Related Experiment Video
Updated: May 22, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities
Florencia Paula Madorsky-Rowdo1, María Laura Lacreu, José Mordoh
1Laboratorio de Cancerología, Fundación Instituto Leloir, IIBBA-CONICET Buenos Aires, Argentina.
Abstract:
To endow the immune system with the capacity to fight cancer has always attracted attention, although the clinical results obtained have been until recently disappointing. Cutaneous melanoma is a highly immunogenic tumor; therefore most of the attempts to produce cancer vaccines have been addressed to this disease. New advances in the comprehension of the mechanisms of antigen presentation by dendritic cells, in the immune responses triggered by adjuvants, as well as the understanding of the role of immunosuppressor molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), which led to the recent approval of the anti-CTLA-4 monoclonal antibody ipilimumab, have opened new hopes about the installment of immunotherapy as a new modality to treat cancer.
Insights
Cancer immunotherapy shows promise, particularly for cutaneous melanoma. Advances in understanding dendritic cells, adjuvants, and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have led to new treatments like ipilimumab.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Cancer immunotherapy aims to harness the immune system to fight tumors.
- Historically, clinical results have been limited, but recent breakthroughs offer new hope.
- Cutaneous melanoma is a highly immunogenic tumor, making it a key target for vaccine development.
Purpose of the Study:
- To review recent advances in cancer immunotherapy.
- To highlight the progress in understanding antigen presentation and immune responses.
- To discuss the significance of cytotoxic T-lymphocyte antigen-4 (CTLA-4) in cancer treatment.
Main Methods:
- Review of recent scientific literature and clinical trial outcomes.
- Analysis of mechanisms in dendritic cell antigen presentation.
- Investigation of immune responses to adjuvants and immunosuppressor molecules.
Main Results:
- Significant progress in understanding immune system mechanisms against cancer.
- The development of novel immunotherapies, including monoclonal antibodies.
- The approval of ipilimumab (anti-CTLA-4) represents a major clinical advancement.
Conclusions:
- Immunotherapy is emerging as a powerful new modality for cancer treatment.
- Advances in immunology have revitalized the field of cancer vaccines.
- Targeting molecules like CTLA-4 offers a promising strategy for treating melanoma and other cancers.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations
01:21Vaccines
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...